Decipher Lethal Prostate Cancer Biology - Urine Metabolomics

Clinical Editorial

Official title: Decipher the Biology of Lethal Prostate Cancer - Urine Metabolomics Profiling in Men Receiving Prostate Biopsy and Men With Diagnosed Prostate Cancer Receiving MCS Supplementation

Summary: Through a better understanding of the biology of significant (lethal) prostate cancer, we hope to develop new markers/targets from urine metabolomics for more effective screening and prevention of significant prostate cancer. In the meantime, with these new markers we may substantially reduce overtreatment of insignificant PC.

Conditions: Significant Prostate Cancer

Keywords: prostate cancer, prostate biopsy, biomarkers, metabolomics, overtreatment, cancer screening, urine, lycopene, proteomics, urine omics

Study type: INTERVENTIONAL

Primary purpose: SCREENING

Phases: NA

Enrollment: 2000 (ESTIMATED)

Status: RECRUITING

Completion: 2027-08-01 (ESTIMATED)

Source Reference

Read the full original publication from the source journal or publisher link below.

DOI

NCT03237702

Open Original Source More Feed Items

Decipher Lethal Prostate Cancer Biology - Urine Metabolomics

Clinical Briefing

Clinical Editorial

Source Reference

Related by Condition/Drug

Targeted biopsy versus combined targeted and systematic biopsy for PI-RADS 4–5 lesions: diagnostic

Circulating Microbial DNA as a Cancer Biomarker: Controlled Evaluation and Technical Pitfalls

Urologic cancer risk after hospital-diagnosed recurrent cystitis: nationwide cohort analysis

Current status of prostate cancer screening research: trends, tools, and challenges

FDA approves Zenbexus (iberdomide) for multiple myeloma, first of a novel drug class

High-fibre diets alter gut microbiota, slow prostate tumour growth and protect intestines after ra